[{"address1": "2000 Sierra Point Parkway", "address2": "Suite 501", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "650 484 0899", "website": "https://dayonebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.", "fullTimeEmployees": 174, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jeremy  Bender M.B.A., Ph.D.", "age": 53, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1048400, "exercisedValue": 0, "unexercisedValue": 64677}, {"maxAge": 1, "name": "Mr. Charles N. York II, M.B.A.", "age": 47, "title": "COO, CFO & Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 760000, "exercisedValue": 0, "unexercisedValue": 24599}, {"maxAge": 1, "name": "Mr. Adam  Dubow J.D.", "age": 57, "title": "General Counsel and Chief Compliance Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 608200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Stubenrauch Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jaa  Roberson", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Davy  Chiodin Ph.D., Pharm.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lauren  Merendino M.B.A.", "age": 48, "title": "Chief Commercial Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Elly  Barry M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 12.4, "open": 12.5, "dayLow": 12.27, "dayHigh": 12.74, "regularMarketPreviousClose": 12.4, "regularMarketOpen": 12.5, "regularMarketDayLow": 12.27, "regularMarketDayHigh": 12.74, "beta": -1.518, "forwardPE": -10.969881, "volume": 1235273, "regularMarketVolume": 1235273, "averageVolume": 1141663, "averageVolume10days": 1360310, "averageDailyVolume10Day": 1360310, "bid": 12.49, "ask": 12.63, "bidSize": 200, "askSize": 100, "marketCap": 1264608896, "fiftyTwoWeekLow": 11.13, "fiftyTwoWeekHigh": 18.07, "priceToSalesTrailing12Months": 12.403842, "fiftyDayAverage": 13.3046, "twoHundredDayAverage": 14.13425, "currency": "USD", "enterpriseValue": 708844544, "profitMargins": -0.82678, "floatShares": 69387293, "sharesOutstanding": 100846000, "sharesShort": 18548290, "sharesShortPriorMonth": 19486769, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.1839, "heldPercentInsiders": 0.16983, "heldPercentInstitutions": 0.93157, "shortRatio": 18.44, "shortPercentOfFloat": 0.22219999, "impliedSharesOutstanding": 100846000, "bookValue": 5.51, "priceToBook": 2.275862, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -84293000, "trailingEps": -0.97, "forwardEps": -1.12, "enterpriseToRevenue": 6.953, "enterpriseToEbitda": -3.449, "52WeekChange": -0.10428572, "SandP52WeekChange": 0.23631513, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "DAWN", "underlyingSymbol": "DAWN", "shortName": "Day One Biopharmaceuticals, Inc", "longName": "Day One Biopharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1622122200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "a17405a3-1622-35cb-92a5-67defd12b1ed", "messageBoardId": "finmb_704589075", "gmtOffSetMilliseconds": -18000000, "currentPrice": 12.54, "targetHighPrice": 48.0, "targetLowPrice": 25.0, "targetMeanPrice": 36.11111, "targetMedianPrice": 34.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 558382976, "totalCashPerShare": 5.537, "ebitda": -205504000, "totalDebt": 2615000, "quickRatio": 14.268, "currentRatio": 14.618, "totalRevenue": 101953000, "debtToEquity": 0.471, "revenuePerShare": 1.144, "returnOnAssets": -0.25426, "returnOnEquity": -0.17838, "grossProfits": 99656000, "freeCashflow": -151710368, "operatingCashflow": -89477000, "grossMargins": 0.97747004, "ebitdaMargins": -2.01567, "operatingMargins": 0.31608, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-18"}]